Last reviewed · How we verify
balanced 6% hydroxyethylstarch 130/0.4
Balanced 6% hydroxyethylstarch 130/0.4 is a synthetic colloid that expands intravascular volume by maintaining oncotic pressure in the bloodstream.
Balanced 6% hydroxyethylstarch 130/0.4 is a synthetic colloid that expands intravascular volume by maintaining oncotic pressure in the bloodstream. Used for Fluid resuscitation and volume replacement in acute blood loss during surgery or trauma, Perioperative volume management in patients requiring colloid support.
At a glance
| Generic name | balanced 6% hydroxyethylstarch 130/0.4 |
|---|---|
| Sponsor | University Hospital Muenster |
| Drug class | Synthetic colloid plasma volume expander |
| Modality | Small molecule |
| Therapeutic area | Critical Care / Anesthesia |
| Phase | FDA-approved |
Mechanism of action
Hydroxyethylstarch (HES) is a large polysaccharide polymer that remains in the intravascular space longer than crystalloid solutions, providing sustained volume expansion and maintaining colloid osmotic pressure. The 130/0.4 designation refers to the mean molecular weight (130 kDa) and degree of substitution (0.4), which determine its pharmacokinetic profile. The balanced formulation contains electrolytes in physiologic proportions to reduce hyperchloremic acidosis associated with older HES products.
Approved indications
- Fluid resuscitation and volume replacement in acute blood loss during surgery or trauma
- Perioperative volume management in patients requiring colloid support
Common side effects
- Increased bleeding/coagulopathy
- Acute kidney injury
- Hyperchloremic acidosis
- Anaphylactic reactions
Key clinical trials
- Hydroxyethyl Starch Versus Crystalloid and Postoperative Major Adverse Kidney Complications (PHASE4)
- Colloids in Pediatric Cardiac Surgery: Comparison Between a Balanced and a Non-balanced Colloid (PHASE3)
- Combination of Static Echocardiographic Indices for Prediction of Fluid Responsiveness During Cardiac Surgery
- Perioperative Colloid vs Crystalloid in Patients Undergoing Colorectal Surgery (PHASE4)
- KOREAN Enhanced RecOvery Strategy for Colorectal Surgery (NA)
- The Effect of Hydroxyethylstarch 6% 130/0.4 in a Balanced Electrolyte Solution (Volulyte®) Compared to Gelatine (Geloplasma®) on Microvascular Reactivity and Tissue Oxygen Saturation During Haemodilution Measured With Near-infrared Spectroscopy (NA)
- Use of Two Modern Hydroxyethyl Starch Solutions in Major Urological Procedures (PHASE4)
- Scandinavian Starch for Severe Sepsis/Septic Shock Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: